JCO oncology practice最新文献

{"title":"Natural and Assisted Conceptions in Male Patients With Blood Cancers Who Stored Their Semen for Fertility Preservation.","authors":"Marco Reschini, Elena Sanzani, Francesca Tondo, Mattia Volpi, Paola Vigano', Edgardo Somigliana, Francesca Filippi, Luca Boeri","doi":"10.1200/OP-24-00888","DOIUrl":"https://doi.org/10.1200/OP-24-00888","url":null,"abstract":"<p><strong>Purpose: </strong>The recent improvement in the prognosis of blood cancers has focused attention toward fertility preservation. We aimed to provide real-world insights into sperm quality and rate of conception, both naturally and through assisted reproductive technology (ART), in men who stored their semen before treatments for hematologic cancers.</p><p><strong>Materials and methods: </strong>Patients with hematologic cancer who cryopreserved semen between 1987 and 2018 had a postbanking follow-up and survived for at least 5 years after therapies were included. A total of N = 464 patients were selected.</p><p><strong>Results: </strong>Overall, n = 407 survived and n = 255 (63%) underwent a post-treatment sperm analysis, revealing azoospermia in 37% of them. Severe or very severe impairment of spermatogenesis was significantly more prevalent in men affected by leukemias than by lymphomas. About half of cancer survivors (n = 200) sought fatherhood. Seventy-three achieved a natural live birth (37%). Forty-six percent of individuals seeking pregnancy used their cryopreserved samples in ART cycles, resulting in at least one live birth in 52% of them. Overall, 120 of 200 men (60%; 95% CI, 53 to 67) interested in fatherhood successfully had a live birth.</p><p><strong>Conclusion: </strong>Treatments for hematologic cancer have a detrimental impact on semen quality. Semen preserved before therapies and ART are critical for fulfilling the common desire of parenthood in hematologic cancer survivors.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400888"},"PeriodicalIF":4.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Timing Is Everything\": Reflections on Twice-Daily Radiation Treatment for Small Cell Lung Cancer.","authors":"Gregory M M Videtic","doi":"10.1200/OP-25-00166","DOIUrl":"https://doi.org/10.1200/OP-25-00166","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500166"},"PeriodicalIF":4.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Compliance With ASCO Language of Respect Guidelines in Renal Cell Carcinoma Abstracts.","authors":"Nazli Dizman, Ruchi Agarwal, Daniela V Castro, Benjamin Mercier, Xiaochen Li, Regina Barragan-Carrillo, Megan H Wong, Ethan Chan, Akasha Dukkipati, Teebro Paul, Amber Faridi, Jalen Patel, Jaya Goud, Trishita Paul, Malina Ioschici, Zeynep Irem Ozay, Miguel Zugman, Hedyeh Ebrahimi, Alex Chehrazi-Raffle, Tanya B Dorff, Sumanta K Pal, Narjust Florez","doi":"10.1200/OP-24-01039","DOIUrl":"https://doi.org/10.1200/OP-24-01039","url":null,"abstract":"<p><strong>Purpose: </strong>The ASCO Language of Respect (LOR) Guidelines were developed in 2020 to promote patient-respectful language in abstracts and presentations. We assessed adherence to LOR guidelines among renal cell carcinoma (RCC) abstracts presented at the 2023 and 2019 ASCO Annual Meetings.</p><p><strong>Methods: </strong>We systematically evaluated each statement in all RCC abstracts for compliance with the three clauses of LOR guidelines: \"Do not blame patients,\" \"Respect the role of patients,\" and \"Do not dehumanize patients.\" Univariable and multivariable analyses were performed to identify factors associated with noncompliance.</p><p><strong>Results: </strong>Among 101 abstracts from 2023, the majority involved clinical research (66.3%) and had a character count at limit, defined as within 5% of the 2,600-character limit (51.5%). In 60.4% of abstracts, at least one statement violated the LOR guidelines. Proportions of abstracts with one or more statements with dehumanizing, blaming, or disrespectful language were 46.5%, 21.8%, and 1.0%, respectively. Among all variables examined, including research and author characteristics, abstracts at character limit emerged as the only category with significantly higher rates of noncompliance (62.3% <i>v</i> 35.0%, <i>P</i> = .013). Multivariable analyses showed an odds ratio of 3.3 (95% CI, 1.4 to 7.6, <i>P</i> = .006) for abstracts at character limit to have at least one noncompliant statement. Notably, even among abstracts not at character limit, 46.9% contained statements violating the guidelines. Between 2019 and 2023, the rate of statements that violated the LOR guidelines decreased from 71.0% to 60.4%.</p><p><strong>Conclusion: </strong>A significant proportion of RCC abstracts contain language inconsistent with LOR guidelines. Although character limit is a likely contributor, our report highlights the need for our professional societies and abstract reviewers to cultivate greater awareness and adherence to patient-respectful language.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2401039"},"PeriodicalIF":4.7,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Death, Dying, and Disrespect: Failing to Honor Voices due to Systemic Barriers and Medicalization of End-of-Life Care.","authors":"Manali I Patel","doi":"10.1200/OP-25-00180","DOIUrl":"https://doi.org/10.1200/OP-25-00180","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500180"},"PeriodicalIF":4.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines, Counseling Practices, and Fertility Preservation Options for Childhood Cancer Patients in the Nordic-Baltic Region.","authors":"Monika Grubliauskaite, Zivile Gudleviciene, Irma C Oskam, Babak Asadi-Azarbaijani, Kirsi Jahnukainen","doi":"10.1200/OP-24-00623","DOIUrl":"https://doi.org/10.1200/OP-24-00623","url":null,"abstract":"<p><strong>Purpose: </strong>Despite new medicine and treatment options, fertility is impaired for many childhood cancer survivors after gonadotoxic treatment. In the current study, we compiled an overview on the state of fertility preservation (FP) care and limitations for childhood cancer patients throughout the Nordic-Baltic region.</p><p><strong>Materials and methods: </strong>In partnership with the Nordic Society of Pediatric Hematology and Oncology, an anonymous survey was conducted among 23 major pediatric oncology centers in Nordic and Baltic countries. The survey featured 22 multiple-choice and open-ended questions that provided insights into guidelines, available FP options, clinical indications, and counseling.</p><p><strong>Results: </strong>The response rate to the questionnaire was 74% (17 of 23 pediatric oncology centers). The survey revealed that only 65% of the centers have national guidelines on FP at the time. Although all centers offer counseling before treatment by oncologists (88%) or gynecologists (65%), 76% of the centers provide it only to those fulfill inclusion criteria. Additionally, counseling is unavailable for some patients because of age (35%), communication issues (29%), or lack of time (24%). Predominantly, sperm cryopreservation is offered across all centers for pubertal boys, while testicular tissue cryopreservation is provided at 41% of pediatric oncology centers for prepubertal boys. Oocyte cryopreservation is offered to pubertal girls at 88% of the centers, and ovarian tissue cryopreservation is offered to prepubertal and pubertal girls at 82% of the questioned centers.</p><p><strong>Conclusion: </strong>The survey highlights the implementation of FP services status in the Nordic and Baltic countries. However, standardizing FP indications and disseminating guidelines widely is crucial to reduce clinical variability. Addressing issues such as inconsistent counseling, limited collaboration, and unclear risk stratification can drive further improvements.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400623"},"PeriodicalIF":4.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm.","authors":"Oluseyi Abidoye, Prateek Jain, Parminder Singh","doi":"10.1200/OP-24-00758","DOIUrl":"https://doi.org/10.1200/OP-24-00758","url":null,"abstract":"<p><p>Urothelial carcinoma (UC) is the most common malignancy of the urinary tract, with urothelial bladder cancer accounting for approximately 90% of cases. Metastatic UC (mUC) is a particularly aggressive subset that presents significant treatment challenges, especially in patients who are often older than 70 years and have multiple comorbidities. For several decades, cisplatin-based chemotherapy has been the standard first-line treatment for locally advanced (LA) mUC. However, its utility has been limited as many patients are ineligible owing to their health status, and overall survival rates remain suboptimal. Recent advancements, including antibody-drug conjugates and immunotherapies, have begun to reshape the treatment landscape for LA/mUC. The combination of enfortumab vedotin and pembrolizumab has shown promising clinical outcomes. The approval of multiple novel drugs and combination therapies not only provides new opportunities for patient care but also creates the need for physicians to adapt to this evolving therapeutic paradigm. This review explores the latest clinical data on the management of LA/mUC and offers insights into sequencing therapies for patients with LA/mUC.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400758"},"PeriodicalIF":4.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.","authors":"Matthew Wu, Kathryn Russell, Carole M Shaw, Anna B Halpern, Cristina Ghiuzeli, Jacob S Appelbaum, Paul Hendrie, Roland B Walter, Mary-Elizabeth M Percival","doi":"10.1200/OP-24-00734","DOIUrl":"https://doi.org/10.1200/OP-24-00734","url":null,"abstract":"<p><strong>Purpose: </strong>Heart failure is a leading cause of death in patients with AML, who face higher risks of cardiac complications than nonleukemic cancer patients treated with anthracyclines. This study examines factors associated with myocardial dysfunction and recovery occurring during treatment of AML.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with AML who sustained reduced left ventricular ejection fraction (LVEF) during induction therapy at the University of Washington/Fred Hutchinson Cancer Center (2008-2022). Multivariable analysis compared characteristics between patients who eventually recovered LVEF and those who did not, with survival analysis performed by landmark censoring.</p><p><strong>Results: </strong>Of 86 patients with AML diagnosed with systolic dysfunction, 41 (48%) failed to recover LVEF. These patients were more frequently male, older than 60 years, had preexisting cardiovascular risk factors, and leukemias of higher risk. Ischemia-related systolic failure was associated with nonrecovery (B = -2.89, <i>P</i> = .005), whereas chemotherapy-related dysfunction was associated with eventual recovery (B = 1.15, <i>P</i> = .014). Frequent use and higher doses of guideline-directed medical therapy (GDMT) were found among patients who recovered LVEF. Failure to recover cardiac function was associated with a greater incidence of cardiac-specific mortality (51% <i>v</i> 23%, <i>P</i> = .042), although impact on overall survival was unclear.</p><p><strong>Conclusion: </strong>Our retrospective single-center analysis suggests that approximately half of the patients with AML who experience LVEF decline during induction will not recover. Ischemic events during treatment were predictive of nonrecovery. The use of GDMT may improve prognosis for some patients. Given the impact of recovery, we propose the prospective verification and establishment of cardiac management algorithms in patients with AML.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400734"},"PeriodicalIF":4.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last.","authors":"David H Johnson","doi":"10.1200/OP-25-00120","DOIUrl":"https://doi.org/10.1200/OP-25-00120","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500120"},"PeriodicalIF":4.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-Associated Molecules Lead the Way to New Therapies for Small Cell Lung Cancer.","authors":"Cameron Oswalt, Neal Ready","doi":"10.1200/OP-25-00142","DOIUrl":"https://doi.org/10.1200/OP-25-00142","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500142"},"PeriodicalIF":4.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should We Talk About the Weather? Bringing Climate Concerns to the Clinic and Classroom.","authors":"Jeffrey Peppercorn","doi":"10.1200/OP-25-00205","DOIUrl":"https://doi.org/10.1200/OP-25-00205","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500205"},"PeriodicalIF":4.7,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}